Dayton Children’s Hospital Taps Medline as Laboratory Prime Vendor

Agreement follows company’s supply chain solutions during the pandemic

Medline has been selected as Dayton Children’s Hospital’s laboratory prime vendor, entering into a multi-year agreement; an expansion of an existing partnership. For more than eight years, Medline has provided surgical and medical supplies to Dayton Children’s Hospital.

During the pandemic, Medline expanded its role with Dayton Children’s Hospital, helping the procurement team to improve supply chain and product standardization. Solutions included integrating laboratory supply procurement with the hospital’s broader supply chain operations, providing the hospital with a greater understanding of supply needs and available products, as well as potential product substitutions. As a result, the hospital was able to provide optimal care during the pandemic, as well as laboratory services and testing kits to other area hospitals and community residents.

“Because we were in constant communication with Medline, we were confident in our ability to maintain our supplies while also sharing resources with other hospitals and agencies when needed during the pandemic,” said Jennifer Nichols, laboratory finance manager for Dayton Children’s.

Dayton Children’s Hospital was selected by the State of Ohio to deliver regional laboratory care during the pandemic. The hospital also partnered with the Greater Dayton Area Hospital Association (GDAHA) to provide laboratory equipment and testing kits to various hospitals across nine different counties. In addition, Dayton Children’s Hospital opened three, drive-through COVID-19 testing sites for children and adults, and enacted a patient surge plan to care for adult patients when other hospitals did not have available beds.

“Our lab team truly went above and beyond to make sure we could provide all the testing our patients needed, as well as offer testing resources to the community as a whole,” said Melanie Wilson, senior director of laboratory services and medical imaging for Dayton Children’s.

“The keys to navigating these tough times were collaboration and communication,” said Wilson. “Through it all, our supply chain never let us down.”

 Learn more about Medline’s laboratory solutions.

SourceMedline
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy